These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 10426870)

  • 1. Low-dose fibrinolytics and glycoprotein IIb/IIIa receptor blockade for the treatment of acute myocardial infarction.
    Ferrario M; Repetto A; Lucreziotti S; Ardissino D
    Am Heart J; 1999 Aug; 138(2 Pt 2):S121-5. PubMed ID: 10426870
    [No Abstract]   [Full Text] [Related]  

  • 2. IIb/IIIa receptor blockade in acute myocardial infarction.
    Ferguson JJ; Taqi K
    Am Heart J; 1999 Aug; 138(2 Pt 2):S164-70. PubMed ID: 10426877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary stenting and glycoprotein IIb/IIIa inhibitors in acute myocardial infarction.
    Colombo A; Briguori C
    Am Heart J; 1999 Aug; 138(2 Pt 2):S153-7. PubMed ID: 10426875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in antithrombotic therapy of acute myocardial infarction.
    Gensini GF; Comeglio M; Falai M
    Am Heart J; 1999 Aug; 138(2 Pt 2):S171-6. PubMed ID: 10426878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do new devices add to the results of PTCA in acute myocardial infarction?
    Moses J; Moussa I
    Am Heart J; 1999 Aug; 138(2 Pt 2):S158-63. PubMed ID: 10426876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Platelet membrane glycoproteins as site of pharmacological intervention in the treatment of coronary disease].
    Neumann FJ; Gawaz M; Schömig A
    Dtsch Med Wochenschr; 1997 Oct; 122(40):1224-30. PubMed ID: 9378047
    [No Abstract]   [Full Text] [Related]  

  • 7. What do new lytics add to t-PA?
    Van de Werf F
    Am Heart J; 1999 Aug; 138(2 Pt 2):S115-20. PubMed ID: 10426869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conjunctive use of platelet glycoprotein IIb/IIIa antagonists and thrombolytic therapy for acute myocardial infarction.
    Moliterno DJ; Topol EJ
    Thromb Haemost; 1997 Jul; 78(1):214-9. PubMed ID: 9198156
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical trials with glycoprotein IIb/IIIa receptor antagonists in acute coronary syndromes.
    Van de Werf F
    Thromb Haemost; 1997 Jul; 78(1):210-3. PubMed ID: 9198155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of glycoprotein IIb/IIIa inhibitor therapy in acute ST-segment elevation myocardial infarction: current practice and future trends.
    Campbell KR; Ohman EM; Cantor W; Lincoff AM
    Am J Cardiol; 2000 Apr; 85(8A):32C-8C. PubMed ID: 10793178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical studies on glycoprotein IIb/IIIa receptor antagonist].
    Rasmussen LH; Husted SE; Clemmensen PM; Gøtzsche CO; Helqvist S; Kristensen SD; Pedersen KE; Rasmussen K; Rasmussen S
    Ugeskr Laeger; 2000 Oct; 162(44):5944-7. PubMed ID: 11094564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycoprotein IIb/IIIa receptor antagonists: clinical pharmacology in cardiovascular diseases of aging.
    Sebastian M; Makkar R
    Drugs Aging; 1999 Sep; 15(3):207-18. PubMed ID: 10503813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The benefits of platelet glycoprotein IIb/IIIa receptor inhibition during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: drug-specific or class effect?
    Brener SJ
    J Am Coll Cardiol; 2009 May; 53(18):1674-6. PubMed ID: 19406343
    [No Abstract]   [Full Text] [Related]  

  • 14. Glycoprotein IIb/IIIa inhibition in percutaneous coronary interventions.
    Sharma S; Nyitray W; Bhambi B
    JAMA; 2003 Sep; 290(11):1451; author reply 1451. PubMed ID: 13129974
    [No Abstract]   [Full Text] [Related]  

  • 15. Administration of glycoprotein IIb-IIIa inhibitors in patients with ST-segment elevation myocardial infarction.
    Dobesh PP; Kasiar JB
    Pharmacotherapy; 2002 Jul; 22(7):864-88. PubMed ID: 12126220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.
    Kleiman NS; Raizner AE; Jordan R; Wang AL; Norton D; Mace KF; Joshi A; Coller BS; Weisman HF
    J Am Coll Cardiol; 1995 Dec; 26(7):1665-71. PubMed ID: 7594101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Spleen rupture in myocardial infarction after administration of GP IIb-IIIa-antagonists].
    Feldmann C; Deutsch HJ
    Dtsch Med Wochenschr; 2005 Jan; 130(1-2):29-30. PubMed ID: 15619171
    [No Abstract]   [Full Text] [Related]  

  • 18. Combination fibrinolytic therapy and platelet glycoprotein IIb/IIIa receptor blockade in acute myocardial infarction: an emerging solution for reperfusion.
    Kaplan AL; Goldmann B; Ohman EM
    J Emerg Med; 1999; 17(3):589-95. PubMed ID: 10338261
    [No Abstract]   [Full Text] [Related]  

  • 19. Platelet glycoprotein IIb/IIIa receptor blockade in unstable coronary disease.
    Chesebro JH; Badimon JJ
    N Engl J Med; 1998 May; 338(21):1539-41. PubMed ID: 9593795
    [No Abstract]   [Full Text] [Related]  

  • 20. Glycoprotein IIb/IIIa platelet receptor inhibitors: a new dimension in cardiology.
    Tan HC
    Ann Acad Med Singap; 1997 Jul; 26(4):481-8. PubMed ID: 9395815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.